Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial
Androgen receptor pathway inhibitors are often preferred to taxane chemotherapy as a treatment of second or subsequent line in older metastatic castration-resistant prostate cancer patients due to more frequent treatment-related toxicities. Here, we showed that quality of life and pain did not differ significantly with an adapted schedule of cabazitaxel (CBZ), compared with the standard regimen. This CBZ schedule could increase eligibility of older patients for chemotherapy.
Authors
- Antoine Thiery-Vuillemin (ORCID: https://orcid.org/0000-0001-6822-3401)
- Susan Feyerabend (ORCID: https://orcid.org/0000-0002-2261-4228)
- Éric Voog (ORCID: https://orcid.org/0000-0001-8366-8003)
- Carole Hélissey (ORCID: https://orcid.org/0000-0002-7774-349X)
- Frédéric Di Fiore (ORCID: https://orcid.org/0000-0001-7955-6594)
- Éric Amela
- Kaïs Aldabbagh
- Gunhild von Amsberg (ORCID: https://orcid.org/0000-0002-5176-0507)
- Dominique Besson (ORCID: https://orcid.org/0000-0001-8180-4403)
- Olivier Huillard (ORCID: https://orcid.org/0000-0001-9764-0845)
- Eve M. Lepicard
- Stéphane Oudard (ORCID: https://orcid.org/0000-0003-0893-285X)
- Nadine Houédé (ORCID: https://orcid.org/0000-0002-8852-5754)
- Yohann Tran (ORCID: https://orcid.org/0000-0002-5128-0327)
- Emmanuel Sevin (ORCID: https://orcid.org/0009-0003-0702-7521)
- Mostefa Bennamoun (ORCID: https://orcid.org/0000-0002-0878-5186)
- Amandine Quivy
- Ali Hasbini
- Karima Youcef-Ali
- Martin Schostak (ORCID: https://orcid.org/0000-0002-8717-2096)
- Charles Vauchier (ORCID: https://orcid.org/0000-0001-5340-2722)
- Salma Kotti
- David Pfister
- Raffaele Ratta (ORCID: https://orcid.org/0000-0002-2445-415X)
- Philippe Barthélémy (ORCID: https://orcid.org/0009-0006-3868-186X)
- Carolina Saldana (ORCID: https://orcid.org/0000-0001-5303-5723)
- Martin Boegemann
- Déwi Vernerey (ORCID: https://orcid.org/0000-0001-6399-926X)
- Antoine Falcoz
Institutions
- Inserm (FR)
- Universität Hamburg (DE)
- Université Paris-Est Créteil (FR)
- Université de Montpellier (FR)
- Université Paris Cité (FR)
- Fondation de France (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Institut de Cancérologie Strasbourg (FR)
- Institute Mutualiste Montsouris (FR)
- Hôpital Cochin (FR)
- Methodology and Quality of Life Unit in Oncology (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- University Hospital Münster (DE)
- Saint Laurent Polyclinique (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Hôpital Saint-André (FR)
- Martini-Klinik (DE)
- Centre Jean Bernard (FR)
- Hôpital d'Instruction des Armées Bégin (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- University Hospital Magdeburg (DE)
- Clinique Pasteur (FR)
- Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie (FR)
- University Hospital Cologne (DE)
- Centre Hospitalier de Valenciennes (FR)
- Hôpital Foch (FR)
- Université de Rouen Normandie (FR)
- Université de Franche-Comté (FR)
- Otto-von-Guericke-Universität Magdeburg (DE)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1016/j.euo.2024.07.011
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi